A Systemic Review and Meta-analysis of the Effect of SARS-CoV-2 Infection on Sperm Parameters
Objective. Several studies examined the putative effects of SARS-CoV-2 infection on sperm parameters. However, the results remain controversial. In this study, we conducted the most up-to-date systematic review and meta-analysis to investigate the effect of SARS-CoV-2 infection on sperm quality in COVID-19-positive and COVID-19-negative male participants. Method. Seven databases were searched for literature released through June 10, 2022, containing estimates for the outcomes of interest. Using a random-effects model (REM) or a fixed-effects model (FEM), we analyzed the pooled results. The quality of all included studies was assessed by the Newcastle-Ottawa scale. In addition, we performed a quantitative and subgroup analysis of semen data across all included studies. Results. Fourteen studies were extracted from 10 publications, involving a total of 1174 participates for meta-analysis. Sperm parameters of 521 COVID-19 male patients and 653 controls were analyzed. In 8 case-control studies, the pooled mean difference (MD) of total sperm motility was -5.37% (95% confidence interval (CI): -8.47 to -2.28; p<0.05), suggesting that total motility was significantly impaired in male COVID-19 cases. Subgroup analysis showed a significant decrease in semen volume, sperm concentration, and total motility in 238 patients with a recovery time of less than 90 days. Moreover, in the other 6 included pre- to post-COVID-19 studies, the pooled MDs of sperm concentration, total sperm count, total motility, progressive motility, and normal morphology were −6.54×106/ml (95% CI: -10.27 to -2.81; p<0.05), −38.89×106 (95% CI: -59.20 to -18.58; p<0.05), -7.21% (95% CI: -14.36 to -0.07; p<0.05), -5.12% (95% CI: -8.71 to -1.53; p<0.05), and -1.52% (95% CI: -2.88 to -0.16; p<0.05), respectively, which indicate SARS-CoV-2 infection significantly affected these five sperm parameters. Conclusion. Our results revealed that SARS-CoV-2 infection was significantly correlated with decreased sperm quality. Of six sperm parameters, total motility and sperm concentration were the most significantly decreased parameters. These results suggest a possible negative influence of SARS-CoV-2 infection on testicular function and male fertility. Given the potential detrimental effect of SARS-CoV-2 on semen quality, male reproductive health should be monitored closely in patients with COVID-19. This trial is registered with CRD42021275823..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2022 |
|---|---|
| Enthalten in: |
Research - (2022) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xi Chen [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.34133/2022/9835731 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ033044724 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ033044724 | ||
| 003 | DE-627 | ||
| 005 | 20240414131324.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.34133/2022/9835731 |2 doi | |
| 035 | |a (DE-627)DOAJ033044724 | ||
| 035 | |a (DE-599)DOAJ7518e18e3e2545028c29c8470cb3de2c | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Xi Chen |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Systemic Review and Meta-analysis of the Effect of SARS-CoV-2 Infection on Sperm Parameters |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Objective. Several studies examined the putative effects of SARS-CoV-2 infection on sperm parameters. However, the results remain controversial. In this study, we conducted the most up-to-date systematic review and meta-analysis to investigate the effect of SARS-CoV-2 infection on sperm quality in COVID-19-positive and COVID-19-negative male participants. Method. Seven databases were searched for literature released through June 10, 2022, containing estimates for the outcomes of interest. Using a random-effects model (REM) or a fixed-effects model (FEM), we analyzed the pooled results. The quality of all included studies was assessed by the Newcastle-Ottawa scale. In addition, we performed a quantitative and subgroup analysis of semen data across all included studies. Results. Fourteen studies were extracted from 10 publications, involving a total of 1174 participates for meta-analysis. Sperm parameters of 521 COVID-19 male patients and 653 controls were analyzed. In 8 case-control studies, the pooled mean difference (MD) of total sperm motility was -5.37% (95% confidence interval (CI): -8.47 to -2.28; p<0.05), suggesting that total motility was significantly impaired in male COVID-19 cases. Subgroup analysis showed a significant decrease in semen volume, sperm concentration, and total motility in 238 patients with a recovery time of less than 90 days. Moreover, in the other 6 included pre- to post-COVID-19 studies, the pooled MDs of sperm concentration, total sperm count, total motility, progressive motility, and normal morphology were −6.54×106/ml (95% CI: -10.27 to -2.81; p<0.05), −38.89×106 (95% CI: -59.20 to -18.58; p<0.05), -7.21% (95% CI: -14.36 to -0.07; p<0.05), -5.12% (95% CI: -8.71 to -1.53; p<0.05), and -1.52% (95% CI: -2.88 to -0.16; p<0.05), respectively, which indicate SARS-CoV-2 infection significantly affected these five sperm parameters. Conclusion. Our results revealed that SARS-CoV-2 infection was significantly correlated with decreased sperm quality. Of six sperm parameters, total motility and sperm concentration were the most significantly decreased parameters. These results suggest a possible negative influence of SARS-CoV-2 infection on testicular function and male fertility. Given the potential detrimental effect of SARS-CoV-2 on semen quality, male reproductive health should be monitored closely in patients with COVID-19. This trial is registered with CRD42021275823. | ||
| 653 | 0 | |a Science | |
| 653 | 0 | |a Q | |
| 700 | 0 | |a Jinli Ding |e verfasserin |4 aut | |
| 700 | 0 | |a Miao Liu |e verfasserin |4 aut | |
| 700 | 0 | |a Kai Xing |e verfasserin |4 aut | |
| 700 | 0 | |a Peng Ye |e verfasserin |4 aut | |
| 700 | 0 | |a Junxia Min |e verfasserin |4 aut | |
| 700 | 0 | |a Yan Zhang |e verfasserin |4 aut | |
| 700 | 0 | |a Tailang Yin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Research |d American Association for the Advancement of Science (AAAS), 2018 |g (2022) |w (DE-627)DOAJ000141518 |x 26395274 |7 nnns |
| 773 | 1 | 8 | |g year:2022 |
| 856 | 4 | 0 | |u https://doi.org/10.34133/2022/9835731 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/7518e18e3e2545028c29c8470cb3de2c |z kostenfrei |
| 856 | 4 | 0 | |u http://dx.doi.org/10.34133/2022/9835731 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2639-5274 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |j 2022 | ||